Syros Historical Cash Flow
| SYRS Stock | USD 0.18 0.01 3.06% |
Analysis of Syros Pharmaceuticals cash flow over time is an excellent tool to project Syros Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 1.9 M or Other Non Cash Items of 44.8 M as it is a great indicator of Syros Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Syros Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Syros Pharmaceuticals is a good buy for the upcoming year.
Syros |
About Syros Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Syros balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Syros's non-liquid assets can be easily converted into cash.
Syros Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Syros Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Syros Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Syros Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.At this time, Syros Pharmaceuticals' Change Receivables is comparatively stable compared to the past year. Dividends Paid is likely to gain to about 50.8 M in 2025, whereas Stock Based Compensation is likely to drop slightly above 7.3 M in 2025.
Syros Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Syros Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Syros Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 132.3M | (81.7M) | 75.2M | (28.9M) | (26.0M) | (24.7M) | |
| Stock Based Compensation | 10.9M | 10.4M | 11.4M | 10.4M | 12.0M | 7.3M | |
| Free Cash Flow | (60.7M) | (100.8M) | (124.3M) | (110.0M) | (99.0M) | (94.0M) | |
| Change In Working Capital | 10.1M | (10.6M) | (5.5M) | 5.1M | 4.5M | 4.8M | |
| Begin Period Cash Flow | 44.8M | 177.1M | 95.4M | 170.6M | 196.1M | 205.9M | |
| Other Cashflows From Financing Activities | 40.9M | 439K | 11.7M | 257K | 231.3K | 219.7K | |
| Depreciation | 3.0M | 3.0M | 3.0M | 2.3M | 2.6M | 1.9M | |
| Other Non Cash Items | 2.3M | 706K | (37.3M) | 37.1M | 42.7M | 44.8M | |
| Capital Expenditures | 3.3M | 1.2M | 1.2M | 272K | 312.8K | 297.2K | |
| Total Cash From Operating Activities | (57.4M) | (99.5M) | (123.1M) | (109.7M) | (98.7M) | (93.8M) | |
| Net Income | (84.0M) | (86.6M) | (94.7M) | (164.6M) | (148.1M) | (140.7M) | |
| Total Cash From Financing Activities | 143.0M | 70.5M | 131.0M | 43.5M | 50.0M | 72.6M | |
| End Period Cash Flow | 177.1M | 95.4M | 170.6M | 141.6M | 162.9M | 87.1M | |
| Sale Purchase Of Stock | 433K | 323K | (81K) | 257K | 231.3K | 219.7K | |
| Investments | 50M | (52.7M) | 68.4M | 37.3M | 42.9M | 45.1M | |
| Net Borrowings | (205K) | 39.4M | (265K) | (291K) | (334.7K) | (317.9K) | |
| Total Cashflows From Investing Activities | (11.7M) | 46.7M | (52.7M) | 67.2M | 77.3M | 81.1M | |
| Change To Account Receivables | 20.0M | 7K | 1.3M | 1.7M | 1.9M | 2.0M | |
| Change To Operating Activities | 4.2M | 1.6M | 1.9M | (3.7M) | (3.3M) | (3.2M) | |
| Change To Netincome | 9.8M | 11.3M | (6.1M) | (31.8M) | (28.6M) | (27.2M) | |
| Change To Liabilities | (2.1M) | (464K) | (11.9M) | 5.1M | 4.6M | 4.8M | |
| Cash And Cash Equivalents Changes | 18.1M | (6.0M) | 132.3M | 75.2M | 86.4M | 90.8M | |
| Cash Flows Other Operating | 9.3M | 26.0M | (6.9M) | (4.7M) | (4.2M) | (4.0M) | |
| Other Cashflows From Investing Activities | 50M | (51.4M) | 68.4M | 1.6M | 1.8M | 1.7M | |
| Issuance Of Capital Stock | 102.3M | 70.3M | 119.8M | 43.3M | 49.8M | 86.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.